EGFR and non-small cell lung carcinoma: Sixty-two patients were included in a study conducted by Hong et al. A median PFS of 6.5 vs. 3.3 months (EGFR mutated vs. EGFR not mutated) was considered promising, but further studies of the efficacy of docetaxel plus nintedanib in patients with EGFR-mutated NSCLC are needed.21